• Innogen Pharmaceutical, the first company in Asia and third globally to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, on its  HK$683 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.* 
• Breton Technology, a China-based provider of electric-powered engineering machinery, on its HK$234 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.* 
• CICC and SPDBI as the joint sponsors and other  underwriters on the HK$583 million global offering and listing of BrainAurora Medical, a seasoned player in China’s cognitive impairment digital therapeutics, on the Main Board of the Hong Kong Stock Exchange.*
• Morgan Stanley and CICC as the joint sponsors and other  underwriters on the HK$335 million global offering and listing of Taimei Medical, a digital solution provider for pharmaceutical and medical device R&D and commercialization, on the Main Board of the Hong Kong Stock Exchange.*
• Haitong International as the sole sponsor and other underwriters on the HK$493 million global offering and listing of Qunabox Group Limited, a marketing service provider in China focusing on outdoor marketing for fast-moving consumer goods, on the Main Board of the Hong Kong Stock Exchange.*
• YZY Bio, a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic disease, on its HK$176 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.*

* including projects involved in prior to joining Paul Hastings